MedTrace Logo

Frequency of Care for Peripherally Inserted Central Vascular Access In the Prevention of Marsi

NCT07697170 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2026-07-13

No results posted yet for this study

Summary

This randomized controlled clinical trial evaluates the safety equivalence between weekly and biweekly dressing changes for peripherally inserted central catheters (PICC) in oncology patients receiving outpatient chemotherapy.

The study will assess vascular access functionality, skin integrity including Medical Adhesive-Related Skin Injury (MARSI), and the incidence of catheter-related complications.

A total of 150 adult patients with colon or pancreas cancer receiving chemotherapy and requiring PICC insertion will be randomized into two groups: weekly dressing changes (control group) or biweekly dressing changes every 14 days (intervention group).

Participants will be followed during chemotherapy treatment for a minimum of six cycles and up to twelve sessions. Outcomes include catheter-related complications, patient satisfaction with vascular access care, and quality of life measured using the EORTC QLQ-C30 questionnaire (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire).

Conditions

Interventions

PROCEDURE

Weekly dressing for peripherally inserted central catheters

dressing changes for peripherally inserted central catheters every week

PROCEDURE

15 days dressing change for peripherally inserted central catheters

Each 15 days dressing change for peripherally inserted central catheters

PROCEDURE

peripherally inserted central catheters

peripherally inserted central catheters

Sponsors & Collaborators

  • Fundació Institut Germans Trias i Pujol

    collaborator OTHER

  • Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta

    collaborator OTHER

  • Institut Català d'Oncologia

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-10
Primary Completion
2027-10-01
Completion
2028-02-01

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07697170 on ClinicalTrials.gov